Peptides Isolated from HLA-Cw*0304 Confer Different Degrees of Protection from Natural Killer Cell-mediated Lysis
Overview
Affiliations
HLA class I molecules bind peptides derived from proteins degraded in the cytoplasm and display them for surveillance by the immune system. The recognition of HLA class I molecules by natural killer (NK) cells generally inhibits the lytic process. To investigate the role of peptides in the interaction between HLA class I molecules and NK receptors, we first had to identify representative endogenous peptides. Individual peptides bound to HLA-Cw*0304 were isolated and sequenced by tandem mass spectrometry. These peptides ranged in length from 8 to 11 residues and shared an alanine at position 2 and a C-terminal leucine. The murine transporters associated with antigen processing (TAP)-deficient cell line RMA-S was transfected with HLA-Cw*0304 to test whether HLA molecules loaded with a single peptide could deliver the inhibitory signal to NK cells expressing p58.2, which is a killer cell inhibitory receptor known to interact with HLA molecules bearing the HLA-Cw3 public epitope. We found that, in the absence of exogenous peptides, the HLA-Cw*0304 transfectants were killed at levels comparable to untransfected RMA-S cells whereas protection from lysis required both HLA-Cw*0304 heavy chain expression and an exogenously added HLA-Cw*0304-binding peptide. Importantly, not only were HLA-Cw*0304-binding peptides required for protection, but the ability of individual peptides to provide protection differed widely. These studies indicate that the ability to distinguish between subsets of peptides may be a general feature of HLA class I recognition by NK cells.
Chen S, Zhu H, Jounaidi Y Signal Transduct Target Ther. 2024; 9(1):302.
PMID: 39511139 PMC: 11544004. DOI: 10.1038/s41392-024-02005-w.
Kyobe S, Mwesigwa S, Nkurunungi G, Retshabile G, Egesa M, Katagirya E Int J Mol Sci. 2024; 25(17).
PMID: 39273630 PMC: 11395705. DOI: 10.3390/ijms25179683.
Ravindranath M, Ravindranath N, Amato-Menker C, Hilali F, Filippone E Curr Issues Mol Biol. 2024; 46(7):6961-6985.
PMID: 39057057 PMC: 11276036. DOI: 10.3390/cimb46070416.
Halliez C, Ibrahim H, Otonkoski T, Mallone R Front Endocrinol (Lausanne). 2023; 13:1076683.
PMID: 36726462 PMC: 9885197. DOI: 10.3389/fendo.2022.1076683.
To Be or Not to Be: The Case of Endoplasmic Reticulum Aminopeptidase 2.
Kusnierczyk P Front Immunol. 2022; 13:902567.
PMID: 35769458 PMC: 9234130. DOI: 10.3389/fimmu.2022.902567.